Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis on delirium prevalence in advanced cancer patientsOne in three advanced cancer patients face hidden confusion

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the high pooled delirium prevalence in advanced cancer patients when planning screening.

This is a systematic review and meta-analysis of delirium prevalence in patients with advanced cancer. The authors synthesized data from studies employing an assessment tool, pooling results from 9,007 patients. The main finding was a pooled delirium prevalence of 35.6% (95% CI: 27.2–44.1).

The authors noted considerable heterogeneity among the included studies. A key limitation was the inclusion of only three studies from developing countries, which limits generalizability to low-resource settings. The review did not report on specific interventions, comparators, or safety outcomes.

The authors highlighted the necessity for early screening, prevention, and treatment of delirium in this population. However, they emphasized that the results should be interpreted with caution. The evidence base has notable gaps, and generalizability to low-resource settings is limited.

Practice relevance is restrained, focusing on the importance of awareness and early intervention. The review does not provide specific guidance on screening tools or treatment protocols, as these were not the focus of the synthesized evidence.

Imagine a loved one with advanced cancer who suddenly becomes confused, agitated, or hard to wake. This is delirium, and it is more common than many families expect. It can be frightening, and it often signals a medical issue that needs quick attention.

A new review looked at how often delirium happens in people with advanced cancer. The goal was to give a clear picture for patients, caregivers, and clinicians. The hope is that earlier recognition can lead to better support and treatment.

Delirium is a sudden change in attention and thinking. It can include disorientation, hallucinations, or sleepiness. It is different from dementia, which is a gradual decline. Delirium can come and go, and it often signals stress on the body.

Delirium is a major source of distress for patients and families. It can make communication harder and care decisions more complex. It can also lengthen hospital stays and increase the risk of falls or other complications.

But here is the twist. Many past studies reported different rates of delirium in advanced cancer. Some found very high numbers, others much lower. This made it hard to know how common the problem truly is.

This review aimed to solve that problem. The researchers gathered many studies and combined the results. This approach, called a meta-analysis, gives a more reliable estimate than any single study.

Think of delirium as a traffic jam in the brain. Signals that normally flow smoothly get blocked by inflammation, infection, pain, or medicines. The brain’s usual traffic system slows down, and confusion appears.

In this case, the traffic jam is often triggered by the cancer itself or its treatment. Metabolic changes, dehydration, and low oxygen can all play a role. The brain is sensitive, and many stressors can push it off balance.

The researchers searched ten major databases from their start dates through September 15, 2025. They looked for studies that assessed delirium in adults with advanced cancer. They used a structured process to extract data and check study quality.

They included 17 studies with a total of 9,007 patients. Most studies had a low risk of bias, and a few had a moderate risk. The team used a random-effects model to estimate the overall rate of delirium.

The pooled prevalence of delirium was 35.6 percent. That means about one in three patients with advanced cancer experienced delirium. The range of possible true rates was between 27.2 percent and 44.1 percent.

This finding is striking. It suggests that delirium is not rare in this group. It is a common complication that deserves routine attention in cancer care. Early screening can help families and teams respond quickly.

But there is a catch. The rate of delirium varied a lot across studies. This heterogeneity means the true rate may differ depending on the setting, the tools used, and the patient population.

The subgroup analysis showed that the assessment tool matters. Different tools can define and detect delirium in different ways. This can change the reported rates and make comparisons tricky.

Experts in the field note that delirium is under-recognized in cancer care. They stress the need for simple screening tools and clear care pathways. They also highlight the importance of treating reversible causes, such as infection or pain.

This does not mean delirium is inevitable.

For patients and families, the message is practical. If you notice sudden confusion, sleepiness, or agitation, speak up. Ask the care team to screen for delirium and review possible triggers.

Clinicians can use brief bedside tools to check attention and awareness. They can also review medications, manage pain, and treat infections early. These steps can reduce risk and improve comfort.

The review has limitations. The number of studies is modest, and the patient groups varied. Most studies came from higher-resource settings, which limits generalizability to low-income countries.

Future research should test simple screening programs in real-world cancer care. Larger trials can show whether early detection improves outcomes. More studies from low-resource settings are also needed.

Delirium is common in advanced cancer, but it can be managed. With awareness, screening, and timely care, patients and families can navigate this challenge with more support and less fear.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundDelirium is a prevalent complication experienced by patients with advanced cancer and is associated with various adverse outcomes. Although delirium is widely reported among patients with advanced cancer, its estimated prevalence shows considerable heterogeneity across studies. This study aimed to determine the prevalence of delirium among patients with advanced cancer.MethodsA comprehensive literature search was conducted across ten major electronic databases from their inception to September 15, 2025. Data extraction was undertaken using a structured data collection form, and methodological quality was assessed using the Joanna Briggs Institute (JBI) critical appraisal tool for prevalence studies. A random-effects model was used to estimate the pooled prevalence of delirium. Heterogeneity was evaluated using the I2 statistic, with subgroup analyses performed to explore its potential sources.ResultsA total of 17 studies comprising 9,007 patients with advanced cancer yielded a pooled delirium prevalence of 35.6% (95% CI: 27.2–44.1). 13 studies were appraised as having a low overall risk of bias, while 4 were considered to have a moderate risk of bias. The results of subgroup analysis indicated that the pooled prevalence of delirium among patients with advanced cancer exhibited significant variation depending on the assessment tool employed.ConclusionOur findings indicated that delirium is highly prevalent among patients with advanced cancer, highlighting the necessity for early screening, prevention, and treatment. However, these results should be interpreted with caution due to limitations such as the small sample size and considerable heterogeneity. Moreover, the inclusion of only three studies from developing countries limits generalizability to low-resource settings.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251167526.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.